---
title: "Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600196.SH.md"
symbol: "600196.SH"
name: "Shanghai Fosun Pharmaceutical (Group) Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T04:15:56.777Z"
locales:
  - [en](https://longbridge.com/en/quote/600196.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600196.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600196.SH.md)
---

# Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH)

## Company Overview

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.fosunpharma.com](https://www.fosunpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: C (0.46)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 66 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.92% |  |
| Net Profit YoY | 18.86% |  |
| P/B Ratio | 1.31 |  |
| Dividend Ratio | 1.31% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 64189175868.08 |  |
| Revenue | 42274106731.25 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.16% | B |
| Profit Margin | 8.22% | B |
| Gross Margin | 49.70% | B |
| Revenue YoY | 4.92% | C |
| Net Profit YoY | 18.86% | B |
| Total Assets YoY | 4.22% | C |
| Net Assets YoY | 4.63% | C |
| Cash Flow Margin | 152.62% | B |
| OCF YoY | 4.92% | C |
| Turnover | 0.35 | D |
| Gearing Ratio | 48.22% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.92%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "18.86%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.31",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.31%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "64189175868.08",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "42274106731.25",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.16%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "8.22%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "49.70%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "4.92%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "18.86%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.22%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.63%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "152.62%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "4.92%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "48.22%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 18.58 | 39/215 | 24.08 | 22.51 | 21.23 |
| PB | 1.31 | 27/215 | 1.59 | 1.49 | 1.41 |
| PS (TTM) | 1.53 | 23/215 | 1.91 | 1.80 | 1.68 |
| Dividend Yield | 1.31% | 91/215 | 1.20% | 1.14% | 1.06% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-02T16:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 33% |
| Overweight | 2 | 33% |
| Hold | 2 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 23.98 |
| Highest Target | 44.00 |
| Lowest Target | 28.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600196.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600196.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600196.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600196.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**